|
|
|
TESTO-Elisa
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reagents |
96
tests Kit |
Color Code |
Reconstitution |
|
Microtiterplate
with 96 anti TESTO coated wells |
96
wells |
blue |
Ready
for use |
|
Conjugate:
HRP labelled TESTO (HPLC grade) in TRIS-maleate buffer with bovine
gelatin and thymol |
1
vial 1
ml |
red |
Dilute
0.2
ml in 1 vial of conjugate buffer |
|
Conjugate
buffer: Phosphate buffer with bovine gelatin and thymol |
3
vials 21
ml |
red |
Ready
for use |
|
Zero
calibrator in human serum
and thymol |
1
vial lyophilized |
yellow |
Add
1.0 ml distilled water |
|
Calibrator
N = 1 to 5 (see
exact values on vial labels) in human serum and thymol |
5
vials lyophilized |
yellow |
Add
0.5 ml distilled water |
|
Wash
Solution (Tris-HCl) |
1
vial 10
ml |
brown |
Dilute
200 x with distilled water (use a magnetic stirrer). |
|
Controls
- N = 1 or 2 in
human serum with thymol |
2
vials lyophilized |
silver |
Add
0.5 ml distilled water |
|
Chromogen
TMB (Tetramethylbenzydine) in Dimethylformamide |
1
vial 1
ml |
green |
Dilute
0,1
ml into 1 vial of substrate buffer |
|
Substrate
buffer: H2O2 in acetate / citrate buffer |
3
vials 21
ml |
white |
Ready
for use |
|
Stop
solution: H2SO4 1.8N |
1
vial 6
ml |
black |
Ready
for use |
Note: 1.
Use the zero calibrator for sample dilutions.
IV.
SUPPLIES NOT PROVIDED
The
following material is required but not provided in the kit:
1.
High quality distilled water
2.
Pipettes for delivery of: 50 μl, 100 μl, 200 µl, 500 µl and 2
ml (the use of accurate pipettes with disposable plastic tips is recommended)
3.
Vortex mixer
4.
Magnetic stirrer
5.
Horizontal microtiterplate shaker capable of 700 rpm ± 100 rpm
6.
Washer for microtiterplates
7.
Microtiterplate reader capable of reading at 450 nm and 650 nm (or 630
nm)
V.
REAGENT PREPARATION
a.
Calibrators
: Reconstitute the zero calibrator with 1.0 ml distilled water and the other
calibrators with 0.5 ml distilled water.
b.
Controls
: Reconstitute the controls with 0.5 ml distilled water.
c.
Working
TESTO-HRP conjugate : dilute
0.2 ml of the concentrated TESTO-HRP conjugate into one of the vials of
conjugate buffer. Extemporaneous preparation is recommended.
d.
Working
Wash solution : Prepare an
adequate volume of Working Wash solution by adding 199 volumes of distilled
water to 1 volume of Wash Solution (200x). Use a magnetic stirrer to homogenize.
Discard unused Working Wash solution at the end of the day.
e.
Revelation
Solution: pipette 0.1 ml of
the chromogen TMB into one of the vials of substrate buffer (H2O2
in acetate/citrate buffer). Extemporaneous
preparation is recommended.
§
Before opening or reconstitution, all kit components are stable until the
expiry date, indicated on the vial label, if kept at 2 to 8°C.
§
Unused strips must be stored, at 2-8°C, in a sealed bag containing a
desiccant until expiration date.
§
After reconstitution, calibrators and controls are stable for 1 week at 2
to 8°C. For longer storage periods, aliquots should be made and kept at
‑20°C. Avoid successive
freeze thaw cycles.
§
The concentrated Wash Solution is stable at room temperature until
expiration date.
§
Freshly prepared Working Wash solution should be used on the same day.
§
After its first use, the conjugate is stable until expiry date, if kept
in the original well-closed vial at 2 to 8°C.
§
The Working TESTO-HRP conjugate is stable for 4 hours at room temperature
or for 24 hours at 2-8°C, avoid direct sunlight.
§
The freshly prepared revelation solution is stable, before use, for
maximum 15 minutes at room temperature and must be discarded afterwards.
§
Alterations in physical appearance of kit reagents may indicate
instability or deterioration.
VII.
SPECIMEN
COLLECTION
AND
PREPARATION
§
Serum must be kept at 2 - 8°C.
§
If the test is not run within 24 hours, storage in aliquots at -20°C is
recommended. Avoid subsequent
freeze thaw cycles.
§
Prior to use, all samples should be at room temperature. It is recommended to vortex the samples before use.
§
Do not use haemolysed samples.
VIII.
PROCEDURE
A. Handling notes
Do
not use the kit or components beyond expiry date.
Do
not mix materials from different kit lots.
Bring
all the reagents to room temperature prior to use.
Thoroughly
mix all reagents and samples by gentle agitation or swirling.
Perform
calibrators, controls and samples in duplicate.
Vertical alignment is recommended.
Use
a clean plastic container to prepare the Wash Solution.
In
order to avoid cross-contamination, use a clean disposable pipette tip for the
addition of each reagent and sample.
For
the dispensing of the Revelation Solution and the Stop Solution avoid pipettes
with metal parts.
High
precision pipettes or automated pipetting equipment will improve the precision.
Respect the incubation times.
To avoid drift, the time between pipetting of the first calibrator and
the last sample must be limited to the time mentioned in section XIII paragraph
E (Time delay).
Prepare
a calibration
curve for each run, do not use data from previous runs.
The
chromogenic solution should be colourless.
If a dark blue colour develops within a few minutes after preparation,
this indicates that the preparation is unusable and must be discarded.
Dispense
the Revelation Solution within 15 minutes following the washing of the
microtiterplate.
During
incubation with Revelation Solution, avoid direct sunlight on the
microtiterplate.
B. Procedure
1.
Select the required number of strips for the run.
The unused strips should be resealed in the bag with a desiccant and
stored at 2-8°C.
2.
Secure the strips into the holding frame.
3.
Pipette 50 µl of each Calibrator, Control and Sample into the
appropriate wells.
4.
Pipette 200 µl of TESTO-HRP conjugate into all the wells.
5.
Incubate for 2 hours at room temperature on a horizontal shaker set at
700 rpm ± 100 rpm.
6.
Aspirate the liquid from each well.
7.
Wash the plate 3 times by:
§
Dispensing 0.4 ml of
Wash Solution into each well
§
Aspirating the
content of each well
8.
Pipette 200 µl of the freshly prepared revelation solution into each
well within 15 minutes following the washing step.
9.
Incubate the microtiterplate for 30 minutes at room temperature on a
horizontal shaker set at 700 rpm ± 100 rpm, avoid direct sunlight.
10.
Pipette 50 µl of Stop Solution into each well.
11.
Read the absorbencies at 450 nm (reference filter 630 nm or 650 nm)
within 1 hour and calculate the results as described in section XI.
IX.
CALCULATION
OF
RESULTS
1.
Read the plate at 450 nm against a reference filter set at 650 nm (or 630
nm).
2.
Calculate the mean of duplicate determinations.
3.
Calculate for each calibrator, control and sample:
4.
5.
Computer assisted methods can also be used to construct the calibration
curve. If automatic result processing is used, a 4-parameter logistic function
curve fitting is recommended.
6.
By interpolation of the sample (B/B0 (%)) values, determine the TESTO
concentrations of the samples from the calibration curve.
X. TYPICAL DATA
The
following data are for illustration only and should never be used instead of the
real time calibration curve.
|
TESTO-ELISA |
OD
units |
B/B0
(%) values |
|
|
Calibrator
|
0
ng/ml 0.14
ng/ml 0.45
ng/ml 1.45
ng/ml 4.7
ng/ml
15
ng/ml |
1.778 1.569 1.387 1.019 0.648 0.353
|
88 78 57 36 20 |
XI.
PERFORMANCE
AND
LIMITATIONS
A. Detection Limit
Twenty
zero calibrators were assayed along with a set of other calibrators. The
detection limit, defined as the apparent concentration two standard deviations
below the average OD at zero binding, was 0.05 ±
0.02 ng/ml.
B. Specificity
The
percentage of cross-reaction estimated by comparison of the concentration
yielding a 50% inhibition are respectively:
|
Compound |
Cross-Reactivity (%) |
| DiHydroTestosterone Androstenedione 17-β-Estradiol 17-OH-Progesterone Progesterone DHEA DHEA-sulphate Cortisol Danazol Ethinylestradiol Ethisterone
|
0.61 0.76 0.023 0.018 0.035 0.003 0.001 0.002 0.003 <0.001 0.001 |
C. Precision
|
INTRA
ASSAY |
INTER
ASSAY |
||||||
|
Serum |
N |
<
>
± SD (ng/ml) |
CV (%) |
Serum |
N |
<
>
± SD (ng/ml) |
CV (%) |
|
A B |
20 20 |
0.4
± 0.03 4.7
± 0.34 |
8.5 5.2 |
A B |
20 20 |
0.73
±
0.11 2.79
±
0.28 |
15.2 9.9 |
SD
: Standard Deviation; CV: Coefficient of variation
D. Accuracy
RECOVERY
TEST
|
Sample |
Added
TESTO (ng/ml) |
Recovered
TESTO (ng/ml) |
Recovery (%) |
|
Serum Plasma |
5.5 4.1 2.5 1.5 5.5 4.4 2.7 1.8 |
5.7 3.9 2.8 1.6 5.7 4.4 2.8 1.8 |
97 95 112 112 104 100 104 102 |
DILUTION
TEST |
|||
|
Sample |
Dilution |
Theoretical
Concent. (ng/ml) |
Measured
Concent. (ng/ml) |
|
Serum
1 |
1/1 1/2 1/4 1/8 1/16 |
- 2.33 1.16 0.58 0.29 |
4.65 2.62 1.24 0.63 0.33
|
Sample
was diluted with zero calibrator.
Conversion
factor :
From ng/ml to nmol/L : x
3.47
From
nmol/L to ng/ml : x 0.288
To
the best of our knowledge, no international reference material exists for this
parameter.
The
concentrations of the calibrators are determined with the ID-GC/MS reference
method.
F.
Correlation with reference method
Serum
samples from 21 women and 17 men,
ranging from 0.15 to 8.9 ng/ml, were tested with the TESTO-ELISA and a titriated
reference method. The linear
regression shows a good correlation between these two methods:
TESTO-ELISA
= 1.03 (H3 reference) + 0.19
r=0.96 n=38
XII. INTERNAL
QUALITY CONTROL
§
If the results obtained for Control 1 and/or Control 2 are not within the
range specified on the vial label, the results cannot be used unless a
satisfactory explanation for the discrepancy has been given.
§
If desirable, each laboratory can make its own pools of control samples,
which should be kept frozen in aliquots. Controls which contain azide will
interfere with the enzymatic reaction and cannot be used.
§
Acceptance criteria for the difference between the duplicate results of
the samples should rely on Good Laboratory Practises
§
It is recommended that Controls be routinely assayed as unknown samples
to measure assay variability. The
performance of the assay should be monitored with quality control charts of the
controls.
§
It is good practise to check visually the curve fit selected by the
computer.
XIII.
REFERENCE INTERVALS
These
values are given only for guidance; each laboratory should establish its own
normal range of values.
Females: 0.46 ng/ml (0.1 – 1.1)
Males:
6.6 ng/ml (2.6 – 13.5)
XIV.
PRECAUTIONS
AND
WARNINGS
Safety
For
in vitro diagnostic use only.
The
human blood components included in this kit have been tested by European
approved and/or FDA approved methods and found negative for HBsAg, anti-HCV,
anti-HIV-1 and 2. No known method
can offer complete assurance that human blood derivatives will not transmit
hepatitis, AIDS or other infections. Therefore,
handling of reagents, serum or plasma specimens should be in accordance with
local safety procedures.
All
animal products and derivatives have been collected from healthy animals. Bovine
components originate from countries where BSE has not been reported.
Nevertheless, components containing animal substances should be treated as
potentially infectious.
Avoid
any skin contact with all reagents, Stop Solution contains H2SO4,
the chromogen contains TMB in Dimethylformamide, Substrate buffer contains H2O2.
In case of contact, wash thoroughly with water.
Do
not smoke, drink, eat or apply cosmetics in the working area.
Do not pipette by mouth. Use
protective clothing and disposable gloves.
XV.
BIBLIOGRAPHY
1. J.L. ANDREYKO et al. (1986)
Role
of Serum Androgens and Sex Hormone Binding Globulin Capacity in the Evaluation
of Hirsutism in Women.
Clin.
Biochem, Vol. 19, 58‑61.
2. A. BIZZARO et al.
Influence
of Testosterone Therapy on Clinical and Immunological features of Autoimmune
Diseases Associated with Klinefelter's Syndrome
J.
Clin. Endocrin. Metab. Vol. 64, N°1: 32‑36
3. M. CARRABBA et al (1985)
Abnormalities
of Sex hormones in Men with Systemic Lupus Erythematosus.
Clin.
Rheumatology, N° 4: 422‑425.
4.
P. HILL et al. (1985)
Plasma
Testosterone and Breast Cancer.
Eur.J
Cancer Clin. Oncol, Vol. 21, N°10, pp. 1265‑1266
5.
CG. MAHLCK et al (1986)
Testosterone,
SHBG and Albumin in Patients with ovarian carcinoma.
Acta
Obstet. Gynecol. Scand. 65: 533‑S38.
6. D.M.D PERERA et 31 (1987)
Amniotic
Fluid Testosterone and testosterone Glucuronide Levels in the determination of
Foetal Sex.
J.
Steroid Biochem., Vol. 26,N°2,pp.273‑277.
7.
J. TRACHTENBERG (1987)
Experimental
Treatment of Prostatic Cancer by intermittent Hormonal Therapy.
J.
Urology, Vol. 137, pp. 785‑788.
8.
R. MARUYAMA et al. (1987)
Sex‑Steroid‑Binding
Plasma Protein (SBP), Testosterone, Oestradiol and DHEA in Prepuberty and
Puberty.
Acta
Endocrinologica, 114: 60‑67
XVI. SUMMARY OF THE
PROTOCOL
|
|
CALIBRATORS (µl) |
SAMPLE(S) CONTROLS (µl) |
|
Calibrators
(0-5) Controls,
Samples TESTO-HRP
conjugate |
50 - 200 |
- 50 200 |
|
Incubate
for 2 hours at room temperature with continuous shaking at 700 rpm. Aspirate
the contents of each well. Wash
3 times with 400 µl of Wash Solution and aspirate. |
||
|
Revelation
Solution |
200 |
200 |
|
Incubate
for 30 min at room temperature with continuous shaking at 700 rpm. |
||
|
Stop
Solution |
50 |
50 |
|
Read
on a microtiterplate reader and record the absorbance of each well at
450 nm (versus 630 or 650 nm) |
||
|